Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMU9C8F)

• Drug Name: Bavencio Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Merkel cell carcinoma	2C34	Approved	[1]
Colon cancer	2B90.Z	Phase 3	[2]
Gastric adenocarcinoma	2B72	Phase 3	[3]
Head and neck cancer	2D42	Phase 3	[3]
Urothelial carcinoma	2C92.0	Phase 3	[3]
Breast cancer	2C60-2C65	Phase 2	[3]
Melanoma	2C30	Phase 2	[4]
Squamous cell carcinoma	2B60-2D01	Phase 2	[3]
Testicular cancer	2C80	Phase 2	[5]
Haematological malignancy	2B33.Y	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMU9C8F

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Inhibitor	[5]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Merkel cell carcinoma
• ICD Disease Classification: 2C34

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death 1 ligand 1 (PD-L1)	DTT	CD274	4.38E-07	0.37	2.1

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] ClinicalTrials.gov (NCT03827044) Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.